Galectin Therapeutics Inc.
General ticker "GALT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $160.7M (TTM average)
Galectin Therapeutics Inc. follows the US Stock Market performance with the rate: 47.1%.
Estimated limits based on current volatility of 4.3%: low 5.55$, high 6.05$
Factors to consider:
- Total employees count: 14 (+16.7%) as of 2023
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Insufficient funding, Operational and conduct risks, Economic downturns and volatility, Labor/talent shortage/retention, Cybersecurity threats
- Current price 107.8% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.10$, 3.03$]
- 2025-12-31 to 2026-12-31 estimated range: [0.96$, 2.67$]
Short-term GALT quotes
Long-term GALT plot with estimates
Financial data
| YTD | 2024-12-31 |
|---|---|
| Operating Revenue | $0.00MM |
| Operating Expenses | $42.43MM |
| Operating Income | $-42.43MM |
| Non-Operating Income | $-4.61MM |
| Interest Expense | $5.54MM |
| R&D Expense | $36.57MM |
| Income(Loss) | $-47.05MM |
| Profit(Loss)* | $-47.05MM |
| Stockholders Equity | $-103.07MM |
| Assets | $17.50MM |
| Operating Cash Flow | $-41.77MM |
| Financing Cash Flow | $31.23MM |
| Earnings Per Share** | $-0.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.